Big Win on the MIPS Diabetes Cost Measure for 2023!

Resulting from advocacy from Anatomy IT and medical societies, CMS has announced that the Diabetes Cost measure will be modified for 2023 so that the group attribution will mirror the individual clinician attribution. This means that if no one in your group prescribes 2 or more diabetes-related medications, you will not be attributed the measure.

Here is the official language from CMS:

“Cost measures are reviewed and updated with non-substantive changes as part of the annual maintenance process. Through this process, CMS is adding a group-level medication attribution check for the 2023 performance period. Starting in 2023, for a group practice to be attributed Diabetes episodes, at least one clinician within the group practice must have prescribed at least 2 condition-related medications to 2 patients within the current plus prior performance period, which parallels the current clinician-level check.”

Jessica Peterson, MD, MPHWritten By: Jessica Peterson, MD, MPH

About the Author: Jessica Peterson, MD, MPH is the Senior Director of Value-Based Care Policy at Anatomy IT.